Generic Arcoxia is used for treating acute and chronic pain, osteoarthritis and rheumatoid arthritis. It is also used for management of ankylosing spondylitis and relief of chronic musculoskeletal pain. It is also used for treating gout.
More info »
Generic Didronel is used for treating adults with Paget disease, and preventing and treating abnormal bone growth following hip replacement surgery or spinal cord injury. More info »
Generic Indocin is used for treating moderate to severe rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout or certain types of bursitis and tendonitis. More info »
Generic Indocin Extended-Release is used for treating moderate to severe rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout or certain types of bursitis and tendonitis. More info »
Generic Ponstel is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It is used to treat pain or inflammation caused by arthritis. It is also used to treat menstrual pain. More info »
FDA panel votes against wider use of Amgen drug - Fox News
USA TODAYFDA panel votes against wider use of Amgen drugFox NewsThat rate is far higher than has been seen with widely used osteoporosis drugs.
Osteoporosis Medication Linked to Unusual Thigh Fractures - WebMD
Osteoporosis Medication Linked to Unusual Thigh FracturesWebMDOverall, most people with osteoporosis, a loss of bone density over time, will suffer fewer broken bones if they take bisphosphonates, a category of drugs including Actonel, Atelvia, Boniva, and Fosamax that are used to treat the disease.
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical ... - MarketWatch (press release)
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical .
Heart Failure, Osteoporosis Go 'Hand-in-Hand': Researchers - Health.com
MedPage TodayHeart Failure, Osteoporosis Go 'Hand-in-Hand': ResearchersHealth.
Osteoporosis drug developer Radius Health braves chilly IPO market - FierceBiotech
Osteoporosis drug developer Radius Health braves chilly IPO marketFierceBiotechAfter burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million.
